Press Releases

October 30, 2019
Immunomedics Reports Third Quarter 2019 Results and Provides Corporate Update
October 23, 2019
Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019
October 01, 2019
Immunomedics to Present at the 2019 Cantor Global Healthcare Conference
September 28, 2019
Immunomedics Provides Corporate Update
September 12, 2019
Immunomedics to Host Investor Event and Webcast on September 28, 2019 during ESMO Congress
September 04, 2019
Immunomedics Announces Oral Presentation of Sacituzumab-Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress
August 28, 2019
Immunomedics To Participate In Upcoming Healthcare Conferences
August 07, 2019
Immunomedics Reports Second Quarter 2019 Results and Provides Corporate Update
August 01, 2019
Immunomedics to Report Second Quarter 2019 Results and Host Conference Call and Webcast on August 7, 2019
May 29, 2019
Immunomedics To Participate In Upcoming Healthcare Conferences
May 09, 2019
Immunomedics Reports First Quarter 2019 Results and Provides Corporate Update
May 07, 2019
Immunomedics To Participate In Upcoming Healthcare Conferences
May 02, 2019
Immunomedics to Report First Quarter 2019 Results and Host Conference Call and Webcast on May 9, 2019
April 29, 2019
Immunomedics and Everest Medicines Announce Exclusive License Agreement for Sacituzumab Govitecan in East and Southeast Asia Excluding Japan
Immunomedics Announces Departure of Chief Medical Officer
April 08, 2019
Immunomedics Announces Promotion Agreement with Janssen for Erdafitinib in the U.S.
March 07, 2019
Immunomedics Appoints Barbara G. Duncan to Board of Directors
March 04, 2019
Immunomedics to Participate in Cowen and Company 39th Annual Health Care Conference
February 25, 2019
Immunomedics Reports Results For Period Ended December 31, 2018, Strengthens Board And Announnces Senior Leadership Changes
February 20, 2019
Immunomedics Announces Publication of Triple-Negative Breast Cancer Data with Sacituzumab Govitecan in the New England Journal Of Medicine
February 19, 2019
Immunomedics to Report Results for the Quarter and Six Months Ended December 31, 2018 and Host Conference Call and Webcast on February 25, 2019
February 11, 2019
Immunomedics Announces Oral Presentation At The 2019 Genitourinary Cancers Symposium
January 17, 2019
Immunomedics Receives Complete Response Letter from FDA for Sacituzumab Govitecan Biologics License Application